SG10201808984WA - Method for assessing and treating or preventing impaired plasma polar lipid levels - Google Patents

Method for assessing and treating or preventing impaired plasma polar lipid levels

Info

Publication number
SG10201808984WA
SG10201808984WA SG10201808984WA SG10201808984WA SG10201808984WA SG 10201808984W A SG10201808984W A SG 10201808984WA SG 10201808984W A SG10201808984W A SG 10201808984WA SG 10201808984W A SG10201808984W A SG 10201808984WA SG 10201808984W A SG10201808984W A SG 10201808984WA
Authority
SG
Singapore
Prior art keywords
treating
assessing
lipid levels
polar lipid
impaired plasma
Prior art date
Application number
SG10201808984WA
Inventor
Wijk Nick Van
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2014/050233 external-priority patent/WO2015160233A1/en
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of SG10201808984WA publication Critical patent/SG10201808984WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

METHOD FOR ASSESSING AND TREATING OR PREVENTING IMPAIRED PLASMA POLAR LIPID LEVELS The invention pertains to the use of a preparation for the manufacture of a composition 5 for preventing or treating impaired plasma levels of one or more polar lipids such as phosphatidylcholines [PC] selected from the group consisting of phosphatidylcholine diacyl C36:6 [PC aa C36:6], phosphatidylcholine diacyl C38:0 [PC aa C38:0], phosphatidylcholine diacyl C38:6 [PC aa C38:6], phosphatidylcholine diacyl C40:6 [PC aa C40:6] and phosphatidylcholine acyl-alkyl C40:6 [PC ae C40:6] in a preclinical 10 AD or MCI subject or a subject with a high likelihood of developing AD or MCI, and wherein said subject is administered with a composition comprising at least one, preferably at least two, most preferably all B vitamins selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9. 15 [No Suitable Figure]
SG10201808984WA 2014-04-14 2015-04-14 Method for assessing and treating or preventing impaired plasma polar lipid levels SG10201808984WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2014/050233 WO2015160233A1 (en) 2014-04-14 2014-04-14 Method for assessing and treating or preventing impaired plasma polar lipid levels
EP14169740 2014-05-23

Publications (1)

Publication Number Publication Date
SG10201808984WA true SG10201808984WA (en) 2018-11-29

Family

ID=53200262

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201808984WA SG10201808984WA (en) 2014-04-14 2015-04-14 Method for assessing and treating or preventing impaired plasma polar lipid levels
SG11201707964WA SG11201707964WA (en) 2014-04-14 2015-04-14 Method for assessing and treating or preventing impaired plasma polar lipid levels

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201707964WA SG11201707964WA (en) 2014-04-14 2015-04-14 Method for assessing and treating or preventing impaired plasma polar lipid levels

Country Status (6)

Country Link
US (2) US10166252B2 (en)
EP (1) EP3131537A1 (en)
CN (2) CN114588138A (en)
RU (1) RU2705208C2 (en)
SG (2) SG10201808984WA (en)
WO (1) WO2015160247A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3131537A1 (en) * 2014-04-14 2017-02-22 N.V. Nutricia Method for assessing and treating or preventing impaired plasma polar lipid levels
WO2017155386A1 (en) * 2016-03-08 2017-09-14 N.V. Nutricia Method for treating brain atrophy
CN109164194A (en) * 2018-11-02 2019-01-08 质谱生物科技有限公司 The detection method and its kit of lysophosphatidyl cholines in dried blood spot
CN111929430B (en) * 2020-08-14 2021-09-17 宝枫生物科技（北京）有限公司 Biomarkers for diagnosing cognitive disorders and uses thereof
CN114778734B (en) * 2022-04-22 2024-05-07 江南大学 Quantitative determination method and application of polar lipid
CN117147742A (en) * 2023-11-01 2023-12-01 安徽医科大学 Method for quantifying blood content in dry blood spots of filter paper sheet through indicator molecules
CN117233367B (en) * 2023-11-16 2024-02-09 哈尔滨脉图精准技术有限公司 Metabolic marker for pregnancy hypertension risk assessment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180139B1 (en) * 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
US20040043013A1 (en) * 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6596762B2 (en) * 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
RU2361614C2 (en) * 2004-03-24 2009-07-20 ПиДиЭл БАЙОФАРМА, ИНК. APPLICATION OF ANTIBODIES AGAINST α5β1 FOR INHIBITION OF CANCER CELLS PROLIFERATION
EP1800675B1 (en) * 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
WO2009002146A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
BR112013000027A2 (en) * 2010-07-01 2017-07-11 Isis Innovation treatment of cognitive disorders
WO2012091542A1 (en) * 2010-12-28 2012-07-05 N.V. Nutricia Combination of components for the prevention and treatment of frailty
US20120294869A1 (en) * 2011-05-16 2012-11-22 Nevada Cancer Institute Methods for Treating Fatty Liver Disease
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2014027882A1 (en) * 2012-08-13 2014-02-20 N.V. Nutricia Product and method for supporting uridine homeostasis
EP3131537A1 (en) * 2014-04-14 2017-02-22 N.V. Nutricia Method for assessing and treating or preventing impaired plasma polar lipid levels

Also Published As

Publication number Publication date
RU2705208C2 (en) 2019-11-06
RU2016144144A3 (en) 2018-11-23
EP3131537A1 (en) 2017-02-22
US10166252B2 (en) 2019-01-01
SG11201707964WA (en) 2017-11-29
RU2016144144A (en) 2018-05-14
CN106535881A (en) 2017-03-22
US20180117074A1 (en) 2018-05-03
CN114588138A (en) 2022-06-07
WO2015160247A1 (en) 2015-10-22
US20170027979A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
SG10201808984WA (en) Method for assessing and treating or preventing impaired plasma polar lipid levels
MX2019001755A (en) Polyglutamated antifolates and uses thereof.
MX2023005140A (en) FORMULATION FOR INHIBITING FORMATION OF 5-HT <sub>2B</sub> AGONISTS AND METHODS OF USING SAME.
SG10201810723VA (en) Improved t cell compositions
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
WO2013177421A3 (en) Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same
MX2022011742A (en) Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile.
EP4218809A3 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
MY170876A (en) Dairy product and process
WO2015061798A3 (en) Compositions and methods comprising yeast organisms and lipid extracts thereof
PE20150359A1 (en) DIETARY MANAGEMENT OF CELIAC DISEASE AND FOOD ALLERGY
MX2018002546A (en) Compositions comprising an urolithin compound.
CO2017002813A2 (en) Stabilized derivatives of adrenomedullin and their use
MX2015012548A (en) Methods of stimulating infant lung and gut maturation.
MY185605A (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
BR112013022673A2 (en) amount of phenylcarbamate, and method for inhibiting the production of a neurotoxic aggregation protein in an individual
MA40645A (en) Prebiotic inulin based preparation
MX2018000140A (en) Formulations for improving the efficacy of hydrophobic drugs.
MX2016009229A (en) Formulation of liposome rehydration salts.
MY187748A (en) Compositions and method for maintaining/improving cognitive function
PH12015502623A1 (en) Composition and nutritional products with improved emulsion stability
WO2015171643A3 (en) Expression of voltage-gated ion channels in ciliates
PH12015500468B1 (en) Treatment and prevention of acne
PLOS Genetics Staff Correction: Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism